NovelStem International Corp. 2025 Annual Report: Comprehensive Investor Update

Key Highlights from the 2025 Annual Report

• Business Status: NovelStem International Corp. (“NovelStem” or the “Company”) is a holding company whose principal asset is the rights to a licensing agreement, previously held by NewStem, and currently held by Yissum, the technology transfer company of Hebrew University of Jerusalem.
• Financial Position: The Company has limited operating history, minimal revenues, and relies entirely on income from the licensing agreement for cash flow. The Company does not have employees, instead relying on consultants for its operations.
• Dividends: The Company has not paid dividends since changing its business focus in 2018 and does not anticipate paying dividends in the foreseeable future, preferring to use any future earnings to reduce debt and fund possible business expansion or acquisitions.
• Financial Condition and Liquidity: The Company has relied on bridge loans from its Executive Chairman and convertible debt from unrelated parties to fund operations. As of the report, \$100,000 in convertible debt and \$161,867 in bridge loans were outstanding, with maturity extensions granted to June 30, 2026.
• Internal Controls: Material weaknesses in internal controls over financial reporting have been identified, particularly due to insufficient resources to ensure proper segregation of duties. Management is working toward remediation but is hindered by limited financial resources.
• Share Trading and Market Risks: NovelStem’s common stock is quoted on the OTC Pink Market under the symbol “NSTM” but trades in very limited quantities. The Company currently has approximately 49 million shares outstanding, held by about 80 record holders, with recent trading prices ranging from \$0.06 to \$0.08 per share.

Detailed Shareholder and Price-Sensitive Information

1. Business Model and Revenue Dependency

The Company’s future is heavily dependent on the successful monetization and relicensing of the technology license held by Yissum. Currently, NovelStem does not conduct any other business and has no other revenue streams. Any failure to relicense or generate income from this asset could materially impact the Company’s financial health and share value.

2. Operating History and Financial Stability

NovelStem has a limited track record of revenues and operations. It has not demonstrated significant revenue generation or profitability, which increases risk for investors. The Company’s ability to achieve or sustain profitability remains uncertain.

3. Debt and Liquidity Concerns

The Company has funded its operations through short-term borrowings, including:

• \$100,000 in convertible debt from unrelated parties (10% interest, extended to June 30, 2026)
• \$161,867 in bridge loans from the Executive Chairman (10% interest, extended to June 30, 2026)

These loans highlight ongoing liquidity challenges and dependence on external funding sources.

4. Internal Control Weaknesses

Management has identified material weaknesses in internal controls over financial reporting, specifically citing insufficient personnel to ensure proper segregation of duties. As a result, there is a risk of material misstatement in the financial statements, which could impact investor confidence and share value. The Company is actively seeking to address these weaknesses but faces resource constraints.

5. Dividend Policy

The Company does not intend to pay cash dividends in the foreseeable future, choosing instead to retain earnings for debt reduction and growth opportunities. This means shareholders should not expect returns from dividends, and any return on investment will depend solely on the ability to sell shares at a higher price.

6. Market and Trading Risks

The Company’s stock is thinly traded on the OTC Pink Market. Low trading volumes can lead to high volatility and difficulty in selling shares, which may affect share value. The stock’s “penny stock” status further limits its marketability and increases price risk.

7. Potential for Investment Company Classification

There is a risk that the Company could be deemed an investment company under the Investment Company Act of 1940 if the SEC finds that it primarily holds investment securities. This would impose significant additional regulatory burdens and costs.

8. Regulatory and Sarbanes-Oxley Compliance Costs

Compliance with SEC reporting and the Sarbanes-Oxley Act is costly and may strain the Company’s limited resources. Management estimates annual costs related to legal, audit, and compliance functions to be several hundred thousand dollars, which could further erode net income or increase net loss.

9. No Legal Proceedings or Mine Safety Issues

The Company reports no ongoing legal proceedings or mine safety disclosures.

10. Governance

The full board acts as the audit committee, and there is no separate nominating committee. The Company has adopted a Code of Business Conduct and Ethics, and all Section 16(a) reporting requirements have been met.

Potential Share Price Movers

• Success or Failure in Monetizing the License: Any significant update regarding relicensing or commercial deployment of the technology could substantially impact the share price.
• Remediation of Internal Control Weaknesses: Progress in addressing material weaknesses or hiring necessary personnel could improve market confidence.
• Changes in Liquidity Position: New funding, improved revenues, or changes in debt obligations may affect valuation.
• Regulatory Developments: Any indication that the Company may be classified as an investment company or faces regulatory action could be negative.

Conclusion & Outlook

NovelStem International Corp. remains a high-risk, speculative investment, highly dependent on the success of its single licensing asset and its ability to secure ongoing funding. Investors should closely monitor progress regarding the licensing asset, improvements in internal controls, and any developments related to liquidity or regulatory status. The Company’s lack of revenue, thin trading market, and absence of dividends are critical factors to consider before investing.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with a financial advisor before making investment decisions. The Company’s financial position is subject to significant uncertainties and risks as discussed above.

View NovelStem International Corp. Historical chart here